Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Elastic NV (ESTC) vs Heron Therapeutics Inc (HRTX) Price & Performance

Elastic NVTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Elastic NV vs Heron Therapeutics Inc — how do they compare? Elastic NV trades at $95.26 (market cap $9.77B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Elastic NV is far larger — about 132× Heron Therapeutics Inc's market cap, and Elastic NV is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Heron Therapeutics Inc for 35 Days on average.

ESTCHRTX
Market Cap
$9.77B$74.04M
Volume
945,5143,668,095
Sector
TechnologyHealth
52-Week High
$99.91$1.49
52-Week Low
$43.30$0.27
Typical Hold Time
10 Days35 Days
Enterprise Value
$8.91B$180.78M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Elastic NV

Elastic (ESTC) trades at $93.1, down 1.59% on the day, with a bullish technical outlook and strong earnings beats in recent quarters. The company shows robust revenue growth, improving profitability into 2026, and positive sentiment from analysts, with 22 buy ratings and no sells. Recent product launches, including AI-driven metrics and serverless vector database offerings, highlight innovation in its observability and search platforms.

The stock presents a growth opportunity driven by product innovation and expanding profit margins, but risks include high valuation multiples and competitive pressures in the enterprise software sector. Analyst consensus targets $79.50, below the current price, suggesting cautious optimism amid execution risks and market volatility.

Heron Therapeutics Inc

HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.

The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ESTC

No sentiment data available yet.

HRTX
8% Buy92% Sell
Avg holding period · 35 Days

Top news

Latest headlines on both assets

About Elastic NV

Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.

Read more on ESTC →

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →